Cardiff Oncology shares plunge after Q2 earnings miss
Investing.com - Berenberg has reiterated its Buy rating and CHF160.00 price target on Medacta International (SIX:MOVE) following meetings with company management and a visit to production facilities in Switzerland.
The investment firm hosted Medacta’s management at its Swiss Stockpicker Conference in London last week and subsequently toured the company’s manufacturing site in Rancate, Switzerland.
Berenberg also gathered feedback from several surgeons regarding Medacta’s GMK SpheriKA knee implant, which was launched earlier in 2024.
The research firm expressed confidence in Medacta’s continued ability to gain market share in the orthopedics sector, highlighting potential upside to consensus expectations for 2025, particularly within the Knee and Spine segments.
Recent product innovation was cited as a key factor supporting Berenberg’s optimistic outlook on the Swiss medical technology company’s growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.